Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
KN5501
/
Nanjing Enricnk Biotech
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
KN5501
/
Nanjing Enricnk Biotech
New P1 trial:
An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy
(clinicaltrials.gov) - Jun 21, 2024
P1
, N=36, Not yet recruiting,
Sponsor: Changhai Hospital
|
|||||||||
KN5501
/
Nanjing Enricnk Biotech
New P1 trial:
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
(clinicaltrials.gov) - Mar 28, 2024
P1
, N=9, Not yet recruiting,
Sponsor: Changzhou No.2 People's Hospital
|
|||||||||
KN5501
/
Nanjing Enricnk Biotech
New P1 trial:
A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
(clinicaltrials.gov) - Mar 19, 2024
P1
, N=15, Recruiting,
Sponsor: YANRU WANG
|
|||||||||
KN5501
/
Nanjing Enricnk Biotech
Enrollment open:
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
(clinicaltrials.gov) - Aug 28, 2023
P1
, N=12, Recruiting,
Sponsor: Changhai Hospital
Not yet recruiting --> Recruiting
|
|||||||||
KN5501
/
Nanjing Enricnk Biotech
New P1 trial:
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
(clinicaltrials.gov) - Aug 24, 2023
P1
, N=12, Recruiting,
Sponsor: Changhai Hospital
|
|||||||||
KN5501
/
Nanjing Enricnk Biotech
New P1 trial:
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
(clinicaltrials.gov) - Jan 6, 2023
P1
, N=12, Not yet recruiting,
Sponsor: Changhai Hospital